Fig. 4.

Patient proportions for incidence, mortality, and accrual according to race and ethnicity, 2000–2019. Over the 20-year period, White patients were disproportionately-accrued compared to their mortality burden 114% of expected (P < .001), their minority counterparts were significantly under-accrued; Black/African-American 47% of expected (P = .008), Hispanic/Latino 17% of expected (P < .001), Asian/Pacific Islander 33% of expected (P < .001) and Native American/Alaska Native 20% of expected (P = .008). PI: Pacific Islander, AI: Alaska Native. *Data Source: Incidence—CBTRUS: Data provided by CDC’s National Program of Cancer Registries and NCI’s Surveillance, Epidemiology and End Results Program, 2000–2017, Mortality—Incidence-Based Mortality SEER Research Data, (2000–2017), Accrual—Systematic review of the literature published of clinical (Phase I–IV) trials of adult gliomas (2000–2019).